SEC Comment Letter for Nasus Pharma Ltd (NSRX) (CIK 0002029039) (NSRX) — Mar 6, 2026
Nasus Pharma Ltd (NSRX) (CIK 0002029039)
Date: March 6, 2026 · CIK: 0002029039 · Accession: 0000000000-26-002335
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293950
Letter
March 6, 2026 Dan Teleman Chief Executive Officer Nasus Pharma Ltd P.O. Box 284 Tel Aviv, Israel 6100201 Re:Nasus Pharma Ltd Registration Statement on Form F-1 Filed March 2, 2026 File No. 333-293950 Dear Dan Teleman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
March 6, 2026
Dan Teleman
Chief Executive Officer
Nasus Pharma Ltd
P.O. Box 284
Tel Aviv, Israel 6100201
Re:Nasus Pharma Ltd
Registration Statement on Form F-1
Filed March 2, 2026
File No. 333-293950
Dear Dan Teleman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences